REGENXBIO, Inc. (RGNX)
9.32
-0.18
(-1.89%)
USD |
NASDAQ |
Sep 01, 16:00
9.31
-0.01
(-0.11%)
After-Hours: 20:00
REGENXBIO Free Cash Flow : -249.67M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -249.67M |
| March 31, 2026 | -236.40M |
| December 31, 2025 | -126.38M |
| September 30, 2025 | -106.28M |
| June 30, 2025 | -90.71M |
| March 31, 2025 | -86.94M |
| December 31, 2024 | -175.56M |
| September 30, 2024 | -184.74M |
| June 30, 2024 | -194.72M |
| March 31, 2024 | -198.64M |
| December 31, 2023 | -228.37M |
| September 30, 2023 | -231.32M |
| June 30, 2023 | -235.98M |
| March 31, 2023 | -257.07M |
| December 31, 2022 | -238.21M |
| September 30, 2022 | 118.25M |
| June 30, 2022 | 118.70M |
| March 31, 2022 | 139.97M |
| December 31, 2021 | 134.70M |
| September 30, 2021 | -150.34M |
| June 30, 2021 | -137.82M |
| March 31, 2021 | -112.88M |
| Date | Value |
|---|---|
| December 31, 2020 | -80.93M |
| September 30, 2020 | -134.05M |
| June 30, 2020 | -123.35M |
| March 31, 2020 | -127.88M |
| December 31, 2019 | -119.42M |
| September 30, 2019 | -101.92M |
| June 30, 2019 | -93.01M |
| March 31, 2019 | 3.828M |
| December 31, 2018 | 91.37M |
| September 30, 2018 | 84.47M |
| June 30, 2018 | 89.82M |
| March 31, 2018 | 11.05M |
| December 31, 2017 | -65.15M |
| September 30, 2017 | -74.08M |
| June 30, 2017 | -70.54M |
| March 31, 2017 | -68.81M |
| December 31, 2016 | -56.71M |
| September 30, 2016 | -36.42M |
| June 30, 2016 | -30.82M |
| March 31, 2016 | -29.52M |
| December 31, 2015 | -23.00M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.21B |
| Capricor Therapeutics, Inc. | -129.78M |
| Biogen, Inc. | 2.49B |
| United Therapeutics Corp. | 1.084B |
| Ardelyx, Inc. | -17.92M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -62.24M |
| Cash from Investing (Quarterly) | 65.92M |
| Cash from Financing (Quarterly) | 17.57M |
| Free Cash Flow Per Share (Quarterly) | -1.188 |
| Free Cash Flow to Equity (Quarterly) | -65.06M |
| Free Cash Flow to Firm (Quarterly) | -55.20M |
| Free Cash Flow Yield | -51.30% |